Cara Therapeutics | CARA - Pre Tax Profit


Cara Therapeutics reported $-4.91M in Pre-Tax Profit for its fiscal quarter ending in March of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Assertio Holdings USD -2.88M 648K Sep/2024
Cara Therapeutics USD -4.91M 3.17M Mar/2025
Cassava Sciences USD -10.81M 33.41M Sep/2025
Chugai Pharma JPY 169.9B 13.83B Dec/2025
Cipla INR 11.69B 6.85B Dec/2025
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD 56.84M 63.78M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Grifols EUR 257.85M 190.87M Dec/2024
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
J&J USD 4.97B 2.53B Dec/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Pacira USD 9.52M 11.45M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
RedHill Biopharma USD -1.54M 12M Jun/2024
Supernus Pharmaceuticals USD -1.91M 56.04M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024